Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Historical Holders from Q1 2014 to Q1 2025

Symbol
RVNC
CUSIP
761330109
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
105M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
81.6M
Holdings value
$248M
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
175
Number of buys
84
Number of sells
-105
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLAZER CAPITAL, LLC 6.87% $26.3M 7.21M Glazer Capital, LLC Jan 30, 2025
Teoxane SA 6.2% 0% $23.9M 6.55M 0% Teoxane SA Jan 30, 2025
Beryl Capital Management LLC 6.1% $23.2M 6.36M Beryl Capital Management LLC Jan 2, 2025
FRANKLIN RESOURCES INC 4.6% $17.5M 4.78M Franklin Resources, Inc. Sep 30, 2024
Palo Alto Investors LP 1.54% $5.88M 1.61M Patrick Lee, MD Sep 30, 2024

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 0 $0 -$2.6M 0
2024 Q4 81.6M $248M -$34M $3.04 175
2024 Q3 82.5M $428M +$73.6M $5.19 203
2024 Q2 81.4M $209M -$16.4M $2.57 172
2024 Q1 83M $409M +$33.2M $4.92 182
2023 Q4 72.4M $636M -$61.7M $8.79 188
2023 Q3 77.7M $891M -$146M $11.47 181
2023 Q2 81.6M $2.07B +$115M $25.31 210
2023 Q1 76.5M $2.46B +$118M $32.21 215
2022 Q4 73.7M $1.36B +$101M $18.46 186
2022 Q3 67.5M $1.82B +$325M $27.00 175
2022 Q2 55.8M $771M +$8.67M $13.82 152
2022 Q1 54.4M $1.06B +$30M $19.50 146
2021 Q4 52.5M $857M -$86.4M $16.32 139
2021 Q3 54.8M $1.53B +$20.2M $27.86 153
2021 Q2 53.8M $1.59B -$21.4M $29.64 156
2021 Q1 54.6M $1.53B +$56.4M $27.95 145
2020 Q4 52.6M $1.49B +$95.5M $28.34 145
2020 Q3 49.3M $1.24B -$27.1M $25.14 146
2020 Q2 49.9M $1.22B +$35.6M $24.42 135
2020 Q1 49.3M $730M -$25.4M $14.80 120
2019 Q4 50.8M $825M +$130M $16.23 125
2019 Q3 42.6M $554M -$12.4M $13.00 104
2019 Q2 43M $557M +$27.1M $12.97 108
2019 Q1 40.6M $639M +$98.5M $15.76 104
2018 Q4 31.7M $639M +$17.6M $20.13 95
2018 Q3 34M $845M -$21.9M $24.85 107
2018 Q2 31.1M $853M +$18.9M $27.45 107
2018 Q1 34.2M $1.05B -$32.7M $30.80 118
2017 Q4 34.9M $1.25B +$167M $35.75 113
2017 Q3 27.4M $754M -$1.52M $27.55 82
2017 Q2 27.5M $727M +$33.7M $26.40 84
2017 Q1 26.2M $546M +$45.4M $20.80 75
2016 Q4 26.1M $540M +$12.2M $20.70 79
2016 Q3 28.6M $464M -$1.08M $16.21 74
2016 Q2 28.8M $391M +$16.9M $13.60 76
2016 Q1 27.2M $475M -$26M $17.46 82
2015 Q4 27.2M $930M +$190M $34.16 101
2015 Q3 21.6M $644M +$32.8M $29.76 76
2015 Q2 20.4M $652M +$15.9M $31.98 86
2015 Q1 20.6M $426M +$18.6M $20.73 69
2014 Q4 19.8M $335M +$8.32M $16.94 67
2014 Q3 15.7M $303M -$45.1M $19.33 80
2014 Q2 16.4M $556M +$155M $34.00 97
2014 Q1 11.8M $373M +$372M $31.50 65